Chemistry: analytical and immunological testing – Clotting or clotting factor level tests
Reexamination Certificate
1998-12-09
2001-02-13
Scheiner, Laurie (Department: 1648)
Chemistry: analytical and immunological testing
Clotting or clotting factor level tests
C436S501000, C424S178100, C424S183100
Reexamination Certificate
active
06187593
ABSTRACT:
1. FIELD OF THE INVENTION
The subject invention relates a method for the production of monoclonal antibodies. The method utilizes an immunized germfree animal. The invention also provides a method for the use of such monoclonal antibodies, and polyclonal antibodies derived from an immunized germfree animal, for in vitro and in vivo clinical diagnostics and therapeutics. Also, the subject invention provides a fibrin-specific monoclonal antibody.
2. BACKGROUND OF THE INVENTION
Kohler and Milstein are generally credited with having devised the techniques that successfully resulted in the formation of the first monoclonal antibody-producing hybridomas (G. Kohler and C. Milstein, 1975,
Nature
256, 495-497; 1976,
Eur. J., Immunol.
6, 511-519). By fusing antibody-forming cells (spleen B-lymphocytes) with myeloma cells (malignant cells of bone marrow primary tumors) they created a hybrid cell line, arising from a single fused cell hybrid (called a hybridoma or clone). The hybridoma had inherited certain characteristics of both the lymphocytes and the myeloma cell lines. Like the lymphocytes, the hybridoma secreted a single type of immunoglobulin; moreover, like the myeloma cells, the hybridoma had the potential for indefinite cell division. The combination of these two features offered distinct advantages over conventional antisera.
Antisera derived from vaccinated animals are variable mixtures of polyclonal antibodies which never can be reproduced identically. Monoclonal antibodies are highly specific immunoglobulins of a single type. The single type of immunoglobulins secreted by a hybridoma is specific to one and only one antigenic determinant, or epitope, on the antigen, a complex molecule having a multiplicity of antigenic determinants. For instance, if the antigen is a protein, an antigenic determinant may be one of the many peptide sequences (generally 6-7 amino acids in length; M. Z. Atassi, 1980,
Molec. Cell. Biochem.
32, 21-43) within the entire protein molecule. Hence, monoclonal antibodies raised against a single antigen may be distinct from each other depending on the determinant that induced their formation; but for any given hybridoma, all of the antibodies it produces are identical. Furthermore, the hybridoma cell line is easily propagated in vitro or in vivo, and yields monoclonal antibodies in extremely high concentration.
A monoclonal antibody can be utilized as a probe to detect its antigen. Thus, monoclonal antibodies have been used in in vitro diagnostics, for example, radioimmunoassays and enzyme-linked immunoassays (ELISA), and in in vivo diagnostics, e.g. in vivo imaging with a radiolabeled monoclonal antibody. Also, a monoclonal antibody can be utilized as a vehicle for drug delivery to such antibodies' antigen.
However, before a monoclonal antibody can be utilized for such purpose, it is essential that the monoclonal antibody be capable of binding to the antigen of interest; i.e., the target antigen. This procedure is carried out by screening the hybridomas that are formed to determine which hybridomas, if any, produce a monoclonal antibody that is capable of binding to the target antigen. This screening procedure can be very tedious in that numerous, for example, perhaps several thousand, monoclonal antibodies may have to be screened before a hybridoma that produces an antibody that is capable of binding the target antigen is identified. Accordingly, there is the need for a method for the production of monoclonal antibodies that increases the likelihood that the hybridoma will produce an antibody to the target antigen.
3. SUMMARY OF THE INVENTION
The subject invention provides a method for the production of monoclonal antibodies to an antigen comprising:
(a) immunizing a germfree animal with said antigen to permit antibody-producing cells to produce antibodies to said antigen,
(b) removing at least a portion of said antibody-producing cells from said germfree animal,
(c) forming a hybridoma by fusing one of said antibody-producing cells with an immortalizing cell wherein said hybridoma is capable of producing a monoclonal antibody to said antigen,
(d) propagating said hybridoma, and
(e) harvesting the monoclonal antibodies produced by said hybridoma.
The subject invention also provides methods for utilizing a monoclonal antibody or a polyclonal antibody derived from a germfree animal. The subject invention also provides a fibrin-specific monoclonal antibody and methods for utilizing such a monoclonal antibody.
REFERENCES:
patent: 3912805 (1975-10-01), Cayzer et al.
patent: 4036945 (1977-07-01), Haber
patent: 4147765 (1979-04-01), Stephan et al.
patent: 4355023 (1982-10-01), Ehrlich et al.
patent: 4421735 (1983-12-01), Haber et al.
patent: 4438209 (1984-03-01), Mosier
patent: 4550086 (1985-10-01), Reinberz et al.
patent: 4758524 (1988-07-01), Bundensen et al.
patent: 4916070 (1990-04-01), Matsueda et al.
patent: 4927916 (1990-05-01), Matsueda
patent: 5091512 (1992-02-01), Gargan et al.
patent: 122478 (1984-10-01), None
patent: 151239 (1985-08-01), None
patent: 187658 (1986-07-01), None
patent: 0 347 933 (1989-12-01), None
patent: WO 87/06263 (1989-10-01), None
Addonizio et al., 1982, “Spect Imaging of Cardiac Transplant Rejection Using IN-111 Antimyosin Antibody”, J. Nuclear Medicine 14(2):910.
Ammar et al., 1982, “Anti-Fibrin Antibody Labeled With IN-111 For Imaging Thrombi”, J. Nuclear Medicine 14(2):Ab14.
Bode et al., 1985, “Antibody-Directed Urokinase: A Specific Fibrinolytic Agent”, Science 229:765-67.
Colwell et al, 1982, “IgA Hybridomas: A Method for Generation in High Numbers”, J. Immunological Methods 54:259-66.
Ehrlich et al., 1983, “Monoclonal Antibodies to Alpha-Chain Regions of Human Fibrinogen That Participate in Polymer Formation”, Biochemistry 22(18):4184-92.
Elms et al., 1983, “Measurement of Cross-Linked Fibrin Degradation Products—An Immunoassay Using Monoclonal Antibodies”, Thromb. Haemostas. 50(2):591-94.
Francis et al., 1985, “Some studies with monoclonal antibody directed against human fibrinogen”, Am. J. Hemat. 18:111-19.
Gaffney et al., 1985, “Unreliability of Current Serum Fibrin Degradation Product (FDP) Assays”, Thromb. Haemostas. 53(3):301-2.
Hui et al., 1983, “Monoclonal Antibodies to a Synthetic Fibrin-like Peptide Bind to Human Fibrin but not Fibrinogen”, Science 222:1129-32.
Hui et al., 1985, “Immunodetection of Human Fibrin Using Monoclonal Antibody-64C5 in an Extracorporeal Chicken Model”, Thromb. Haemostas. 53(2):524-27.
Kanke et al., 1982, “Detection of Residual Coronary Thrombi After Reperfusion of Experimental Myocardial Infarction Using IN-111 Labeled Monoclonal Antifibrin Antibody”, J. Nuclear Medicine 14(2):910.
Kennel et al., 1983, “Solid Phase Radioimmunoassay of Fragment D of Human Fibrinogen by Use of a Low Affinity Monoclonal Antibody”, Clinical Chemistry 29(5):778-81.
Kennel, 1982, “Binding of Monoclonal Antibody to Protein Antigen in Fluid Phase or Bound to Solid Supports”, J. Immunological Methods 55:1-12.
Koppert et al., 1985, “A Monoclonal Antibody, Specific For Human Fibrinogen, Fibrinopeptide A-Containing Fragments and Not Reacting with Free Fibrinopeptide A”, Blood 66(3):503-507.
Kudryk et al., 1984, “Specificity of a Monoclonal Antibody for the NH2—Terminal Region of Fibrin”, Molecular Immunology 21(1):89-94.
Kudryk et al., 1983, “A Monoclonal Antibody With Ability to Distinguish Between NH2—Terminal Fragments Derived From Fibrinogen And Fibrin”, Mol. Immunology 10(11):1191-1200.
LaFrance et al., 1982, “IN 111 Antimyosin Monoclonal Antibody (AMAb) In Detecting Rejection of Heart Transplants”, J. Nuclear Medicine 14(2):910.
Matsueda et al., 1986, “Structural basis for the species selectivity of a fibrin-specific monoclonal antibody”, Biochemistry 25(6):1451-55.
McCabe et al., 1984, “A Diagnostic-Prognostic Test For Bladder Cancer Using A Monoclonal Antibody-based Enzyme-linked Immunoassay for Detection of Urinary Fibrin(ogen) Degradation Products”, Cancer Res. 44:5886-93.
Muller-Berghaus et al., 1985, “Detection of Fibrin in Plasma by a Monoclonal Antibody Against the Amino-terminus of the
Gargan Paul E.
Pleasants Julian R.
Ploplis Victoria A.
American Biogenetic Sciences Inc.
Pennie & Edmonds LLP
Scheiner Laurie
LandOfFree
Methods for treating a fibrin encapsulated tumor using a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating a fibrin encapsulated tumor using a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating a fibrin encapsulated tumor using a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2604494